U.S. Markets closed

Gilead’s Biktarvy Maintained High Efficacy With No Cases of Treatment-Emergent Resistance Through Three Years in Phase 3 HIV Clinical Trials

FOSTER CITY, Calif.--(BUSINESS WIRE)--

– Data from the Two 144-week Studies in Treatment-naïve Adults Living with HIV Presented at European AIDS Conference (EACS)–

Gilead Sciences, Inc. (GILD) today announced findings from two randomized, double-blind, active-controlled Phase 3 studies (Study 1489 and Study 1490) evaluating the safety and efficacy of Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets) compared with dolutegravir (DTG)-containing regimens for the treatment of HIV-1 infection in adults new to HIV therapy. In both studies, Biktarvy was well-tolerated and demonstrated high rates of virologic suppression through Week 144. These data are being presented at the 17th European AIDS Conference (EACS) in Basel, Switzerland.

“The findings presented today support the value of Biktarvy as an effective treatment that offers durable viral suppression and maintains a high barrier to resistance,” said Diana Brainard, MD, Senior Vice President, HIV and Emerging Viruses, Gilead Sciences. “These longer-term data reaffirm Biktarvy’s role as a first-line treatment option for appropriate adults who are living with HIV and are starting therapy.”

Biktarvy is indicated in the United States as a complete regimen for the treatment of HIV-1 infection in patients who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically suppressed on a stable antiretroviral regimen for at least three months with no history of treatment failure and no known substitutions associated with resistance to the individual components of Biktarvy. Biktarvy carries a Boxed Warning in its U.S. product label regarding the risk of post-treatment acute exacerbation of hepatitis B. See below for Important Safety Information.

Studies 1489 and 1490 randomized 1,274 treatment-naïve adults to receive Biktarvy or either dolutegravir/ abacavir/lamivudine (50/600/300 mg, DTG/ABC/3TC) (Study 1489) or DTG + emtricitabine/tenofovir alafenamide (50/200/25 mg, F/TAF) (Study 1490). The primary endpoint of both studies was virologic suppression, defined as the proportion of participants who were virologically suppressed (HIV-1 RNA levels <50 copies/mL) at Week 48. At the primary endpoint, noninferior efficacy was achieved in both studies and has been previously presented. At Week 144, non-inferiority was maintained from the primary endpoint measurement in both studies at Week 48, with a similar proportion of the Biktarvy group achieving virologic suppression (82 percent; n=518/634) as those taking DTG/ABC/3TC (84 percent; n=265/315) and DTG + F/TAF (84 percent; n=273/325). Across all treatment groups no participants developed treatment failure with treatment-emergent resistance.

“Developing new HIV treatment regimens that can be used in a wide range of people living with HIV is very important,” said Chloe Orkin, MBBCH, FRCP, Clinical Professor of HIV Medicine at Queen Mary University of London. “The three-year results from both Biktarvy studies provide further evidence that it is potent and effective, enabling people living with HIV to maintain an undetectable viral load over the long term.”

There were no discontinuations due to renal events and no cases of proximal renal tubulopathy or Fanconi syndrome in the Biktarvy treatment group. Similar reductions in median estimated glomerular filtration rate (eGFR) were observed across groups (-9.2 mL/min in patients taking Biktarvy vs. -11.7 mL/min in participants taking ABC/DTG/3TC vs. -11.0 mL/min in participants taking DTG + F/TAF) at Week 144. Study 1489 also assessed other laboratory markers of renal and bone safety in patients taking Biktarvy and DTG/ABC/3TC. Participants in both treatment arms demonstrated similar median changes in proteinuria and mean percentage changes in hip and spine bone mineral density (BMD) from baseline. Small, statistically significant differences in the median change from baseline favoring DTG/ABC/3TC were observed for LDL, HDL and total cholesterol to HDL ratio.

Biktarvy was well tolerated through Week 144. Discontinuations due to adverse events were low across all groups (1 percent (n=6/634) for Biktarvy vs. 2 percent (n=5/315) for DTG/ABC/3TC and 2 percent (n=6/325) for DTG + F/TAF). The proportion of drug-related adverse events (all grades) was 26 percent in the Biktarvy arm (n=165/634) vs. 42 percent (n=132/315) for DTG/ABC/3TC and 29 percent (n=94/325) for DTG + F/TAF). The incidence of drug-related nausea was 4 percent for Biktarvy vs. 18 percent for DTG/ABC/3TC and 5 percent for DTG + F/TAF (p<0.0001 for Biktarvy vs. DTG/ABC/3TC). The most commonly reported treatment-emergent adverse events (all grades) were diarrhea (19 percent for Biktarvy vs. 18 percent for DTG/ABC/3TC and 16 percent for DTG + F/TAF), headache (16 percent for Biktarvy vs. 18 percent for DTG/ABC/3TC and 18 percent for DTG + F/TAF) and nasopharyngitis (14 percent for Biktarvy vs.17 percent for DTG/ABC/3TC and 19 percent for DTG + F/TAF).

Study 1489 and Study 1490 are ongoing. Beyond Week 144, study participants will have the option to receive Biktarvy in an open-label extension for up to 96 weeks.

Biktarvy does not cure HIV infection or AIDS.

Important U.S. Safety Information and Indication for Biktarvy

BOXED WARNING: POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B

  • Severe acute exacerbations of hepatitis B have been reported in patients who are coinfected with HIV-1 and HBV and have discontinued products containing emtricitabine (FTC) and/or tenofovir disoproxil fumarate (TDF), and may occur with discontinuation of BIKTARVY. Closely monitor hepatic function with both clinical and laboratory follow-up for at least several months in patients who are coinfected with HIV-1 and HBV and discontinue BIKTARVY. If appropriate, anti-hepatitis B therapy may be warranted.

Contraindications

  • Coadministration: Do not use BIKTARVY with dofetilide or rifampin.

Warnings and precautions

  • Drug interactions: See Contraindications and Drug Interactions sections. Consider the potential for drug interactions prior to and during BIKTARVY therapy and monitor for adverse reactions.
  • Immune reconstitution syndrome, including the occurrence of autoimmune disorders with variable time to onset, has been reported.
  • New onset or worsening renal impairment: Cases of acute renal failure and Fanconi syndrome have been reported with the use of tenofovir prodrugs. In clinical trials of BIKTARVY, there have been no cases of Fanconi syndrome or proximal renal tubulopathy (PRT). Do not initiate BIKTARVY in patients with estimated creatinine clearance (CrCl) <30 mL/min. Patients with impaired renal function and/or taking nephrotoxic agents (including NSAIDs) are at increased risk of renal-related adverse reactions. Discontinue BIKTARVY in patients who develop clinically significant decreases in renal function or evidence of Fanconi syndrome.
    Renal monitoring: Prior to or when initiating BIKTARVY and during therapy, assess serum creatinine, CrCl, urine glucose, and urine protein in all patients as clinically appropriate. In patients with chronic kidney disease, assess serum phosphorus.
  • Lactic acidosis and severe hepatomegaly with steatosis: Fatal cases have been reported with the use of nucleoside analogs, including FTC and TDF. Discontinue BIKTARVY if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity develop, including hepatomegaly and steatosis in the absence of marked transaminase elevations.

Adverse reactions

  • Most common adverse reactions (incidence ≥5%; all grades) in clinical studies through week 144 were diarrhea (6%), nausea (6%), and headache (5%).

Drug interactions

  • Prescribing information: Consult the full prescribing information for BIKTARVY for more information on Contraindications, Warnings, and potentially significant drug interactions, including clinical comments.
  • Enzymes/transporters: Drugs that induce P-gp or induce both CYP3A and UGT1A1 can substantially decrease the concentration of components of BIKTARVY. Drugs that inhibit P-gp, BCRP, or inhibit both CYP3A and UGT1A1 may significantly increase the concentrations of components of BIKTARVY. BIKTARVY can increase the concentration of drugs that are substrates of OCT2 or MATE1.
  • Drugs affecting renal function: Coadministration of BIKTARVY with drugs that reduce renal function or compete for active tubular secretion may increase concentrations of FTC and tenofovir and the risk of adverse reactions.

Dosage and administration

  • Dosage: Patients weighing ≥25 kg: 1 tablet taken once daily with or without food.
  • Renal impairment: Not recommended in patients with CrCl <30 mL/min.
  • Hepatic impairment: Not recommended in patients with severe hepatic impairment.
    • Prior to or when initiating: Test patients for HBV infection.
    • Prior to or when initiating, and during treatment: As clinically appropriate, assess serum creatinine, CrCl, urine glucose, and urine protein in all patients. In patients with chronic kidney disease, assess serum phosphorus.

Pregnancy and lactation

  • Pregnancy: There is insufficient human data on the use of BIKTARVY during pregnancy. Dolutegravir, another integrase inhibitor, has been associated with neural tube defects. Discuss the benefit-risk of using BIKTARVY during pregnancy and conception. An Antiretroviral Pregnancy Registry (APR) has been established. Available data from the APR for FTC shows no difference in the rates of birth defects compared with a US reference population.
  • Lactation: Women infected with HIV-1 should be instructed not to breastfeed, due to the potential for HIV-1 transmission.

INDICATION

Biktarvy is indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 25 kg who have no antiretroviral (ARV) treatment history or to replace the current ARV regimen in those who are virologically suppressed (HIV-1 RNA <50 copies per mL) on a stable ARV regimen with no history of treatment failure and no known resistance to any component of Biktarvy.

About Gilead Sciences

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.

For more than 30 years, Gilead has been a leading innovator in the field of HIV, driving advances in treatment, prevention, testing and linkage to care, and cure research. Today, it’s estimated that more than 12 million people living with HIV globally receive antiretroviral therapy provided by Gilead or one of the company’s manufacturing partners.

For more information on Gilead Sciences, please visit the company’s website at www.gilead.com.

Forward-Looking Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the possibility of unfavorable results from ongoing and additional clinical trials involving Biktarvy. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2019, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.

U.S. full Prescribing Information for Biktarvy, including BOXED WARNING, is available at www.gilead.com

Biktarvy, Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc. or its related companies.

For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191106005418/en/

  • Business
    Thomson Reuters StreetEvents

    Edited Transcript of FALC earnings conference call or presentation 19-Nov-19 9:30pm GMT

    Good afternoon, and thank you for joining us to discuss FalconStor Software's Q3 2019 Earnings Call. Todd Brooks, Falconstor's Chief Executive Officer; and Brad Wolfe, Chief Financial Officer, will discuss the company's results and activities, and will open the call to your questions. The company's results and activities -- I would like to advise all participants that today's discussion may contain what some consider forward-looking statements.

  • We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth
    Business
    Simply Wall St.

    We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth

    So should SpringWorks Therapeutics (NASDAQ:SWTX) shareholders be worried about its cash burn? In this report, we will consider the company's annual negative free cash flow, henceforth referring to it as the 'cash burn'. Does SpringWorks Therapeutics Have A Long Cash Runway?

  • Hedge Funds Are Buying Amplify Energy Corp. (AMPY)
    Business
    Insider Monkey

    Hedge Funds Are Buying Amplify Energy Corp. (AMPY)

    With this in mind, as the current round of 13F filings has just ended, let's examine the smart money sentiment towards Amplify Energy Corp. (NYSE:AMPY). Is Amplify Energy Corp. (NYSE:AMPY) a bargain? Money managers are buying.

  • Billionaire George Soros Snaps Up These 3 High-Yield Dividend Stocks
    Business
    TipRanks

    Billionaire George Soros Snaps Up These 3 High-Yield Dividend Stocks

    To watch Boyd's track record, click here) BP shares have received three recent Buy ratings, giving the stock a unanimous 'Strong Buy' from the analyst consensus. The average price target stands tall at $51.33 -- indicating a robust upside potential of 39%. See BP stock analysis on TipRanks) BP wasn't the only energy industry company that Soros was interested in.

  • World
    Oilprice.com

    The Decisive Battle For Libya’s Oil Has Begun

    General Khalifa Haftar has announced “the decisive battle and the advance on the heart of Tripoli,” after eight months of trying to take over the seat of the UN-recognized Government of National Accord with his eastern-affiliated militia the Libyan National Army. The LNA's offensive against Tripoli began this spring and it came as a shock to many after Haftar had been working with the GNA-affiliated National Oil Corporation for a couple of years after the LNA freed Libya's oil exporting terminals from the Petroleum Facilities Guard that was stopping any exports of the commodity, which is vital for Libya. Just last month, for example, forces loyal to the Government of National Accord seized control of the El Feel field, which produces about 73,000 bpd, from Haftar's army.

  • Is IAMGOLD Corporation (IAG) A Good Stock To Buy?
    Business
    Insider Monkey

    Is IAMGOLD Corporation (IAG) A Good Stock To Buy?

    We were also able to identify in advance a select group of hedge fund holdings that underperformed the market by 10 percentage points annually between 2006 and 2017. Interestingly the margin of underperformance of these stocks has been increasing in recent years. Investors who are long the market and short these stocks would have returned more than 27% annually between 2015 and 2017.

  • Bristol-Myers wins $752 million in U.S. patent case against Gilead
    Business
    Reuters

    Bristol-Myers wins $752 million in U.S. patent case against Gilead

    Bristol-Myers Squibb Co on Friday said it won a $752 million jury verdict against Gilead Sciences Inc in a U.S. patent dispute relating to technology for treating cancer. A jury in Los Angeles awarded the damages after finding that Yescarta, a treatment sold by Gilead's Kite Pharma unit, infringed on a patent exclusively licensed by Bristol-Myers' Juno Therapeutics division. The patent at issue in the lawsuit, which Juno licenses from the Memorial Sloan Kettering Cancer Center in New York, relates to CAR T-cell immunotherapy for cancer.

  • General Electric climbs after UBS upgrade
    Business
    Yahoo Finance Video

    General Electric climbs after UBS upgrade

    GE shares are climbing after UBS upgraded the stock to a 'buy' and raised its price target. Yahoo Finance's Brian Cheung joins Seana Smith on The Ticker to discuss.

  • Iran Demands $6 Billion Oil Payment From South Korea: Chosun
    World
    Bloomberg

    Iran Demands $6 Billion Oil Payment From South Korea: Chosun

    Iran's Foreign Ministry called in the South Korean ambassador last month to demand payment of 7 trillion won ($6 billion) for oil it sold to the Asian country, Chosun Ilbo reported, citing officials it didn't identify. Iran expressed “strong regret” over Seoul's failure to complete the payment, which has been deposited at two South Korean banks without being transferred to Iran's central bank for years due to U.S. sanctions against the Middle Eastern country, the newspaper said. It added that other Iranian authorities including the central bank also complained.

  • Is Yext, Inc. (YEXT) A Good Stock To Buy?
    Business
    Insider Monkey

    Is Yext, Inc. (YEXT) A Good Stock To Buy?

    At Insider Monkey, we pore over the filings of nearly 750 top investment firms every quarter, a process we have now completed for the latest reporting period. In this article, we will use that wealth of knowledge to determine whether or not Yext, Inc. (NYSE:YEXT) makes for a good investment right now. Is Yext, Inc. (NYSE:YEXT) an exceptional stock to buy now?

  • Should The J. M. Smucker Company (NYSE:SJM) Be Part Of Your Dividend Portfolio?
    Business
    Simply Wall St.

    Should The J. M. Smucker Company (NYSE:SJM) Be Part Of Your Dividend Portfolio?

    Today we'll take a closer look at The J. M. Smucker Company (NYSE:SJM) from a dividend investor's perspective. With J. M. Smucker yielding 3.4% and having paid a dividend for over 10 years, many investors likely find the company quite interesting. There are a few simple ways to reduce the risks of buying J. M. Smucker for its dividend, and we'll go through these below.

  • Mercedes Delays Electric Debut After Jaguar and Audi SUVs Flop
    Business
    Bloomberg

    Mercedes Delays Electric Debut After Jaguar and Audi SUVs Flop

    Daimler AG's luxury brand will start sales of the EQC crossover in 2021 rather than early next year. The world's top-seller of premium autos has touted the EQC and the series of battery-powered models it has planned under the EQ sub-brand as an answer both to Tesla and its traditional rivals. Jaguar has sold 2,418 I-Pace SUVs in the U.S. this year through November, while Audi has delivered 4,623 e-tron crossovers, according to InsideEVs.

  • Business
    Reuters

    California governor rejects PG&E bankruptcy reorganization plan

    California Governor Gavin Newsom on Friday rejected a bankruptcy reorganization plan submitted by PG&E Corp, the state's largest investor-owned utility, saying its proposal fails to meet the requirements of a recently enacted wildfire law. The decision by Newsom, sent to PG&E in a letter, complicates the company's push to exit bankruptcy and provide billions of dollars to victims of devastating wildfires in 2017 and 2018 sparked by the utility's power lines. The embattled utility now has until Tuesday to further amend its plan to Newsom's satisfaction, but his criticism of the reorganization package as it was presented by PG&E a day earlier was sweeping.

  • Hedge Funds Are Dumping NIO Limited (NIO)
    Business
    Insider Monkey

    Hedge Funds Are Dumping NIO Limited (NIO)

    Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that's why their assets under management continue to swell). NIO Limited (NYSE:NIO) was in 13 hedge funds' portfolios at the end of the third quarter of 2019. There were 14 hedge funds in our database with NIO holdings at the end of the previous quarter.

  • Costco earnings beat but revenue falls short
    Business
    Yahoo Finance Video

    Costco earnings beat but revenue falls short

    Costco Wholesale reported mixed quarterly results, earnings beat but the company's revenue fell short. Yahoo Finance's Heidi Chung joins Seana Smith on The Ticker to discuss.

  • If You Like EPS Growth Then Check Out JD.com (NASDAQ:JD) Before It's Too Late
    Business
    Simply Wall St.

    If You Like EPS Growth Then Check Out JD.com (NASDAQ:JD) Before It's Too Late

    Like the last firework on New Year's Eve accelerating into the sky, JD.com's EPS shot from CN¥0.98 to CN¥2.58, over the last year. Year on year growth of 163% is certainly a sight to behold. I like to take a look at earnings before interest and (EBIT) tax margins, as well as revenue growth, to get another take on the quality of the company's growth.

  • A Much Better Dividend Stock Than These Dividend Darlings
    Business
    Insider Monkey

    A Much Better Dividend Stock Than These Dividend Darlings

    Dividend investors usually focus on companies that have a long track record of increasing their dividends year after year. The companies with at least 25 years of consecutive dividend increases are especially favored by income oriented investors. In these situations, the losses due to share price decline might wipe out the dividend income that has been collected over the years.

  • 3D Systems Corporation (DDD): Hedge Funds Are Snapping Up
    Business
    Insider Monkey

    3D Systems Corporation (DDD): Hedge Funds Are Snapping Up

    Hedge funds are known to underperform the bull markets but that's not because they are bad at investing. Truth be told, most hedge fund managers and other smaller players within this industry are very smart and skilled investors. Hedge funds underperform because they are hedged.

  • Why Marathon Oil Corporation's (NYSE:MRO) High P/E Ratio Isn't Necessarily A Bad Thing
    Business
    Simply Wall St.

    Why Marathon Oil Corporation's (NYSE:MRO) High P/E Ratio Isn't Necessarily A Bad Thing

    That isn't a good or a bad thing on its own, but a high P/E means that buyers have a higher opinion of the business's prospects, relative to stocks with a lower P/E. Does Marathon Oil Have A Relatively High Or Low P/E For Its Industry? We can get an indication of market expectations by looking at the P/E ratio. You can see in the image below that the average P/E (10.0) for companies in the oil and gas industry is lower than Marathon Oil's P/E. That means that the market expects Marathon Oil will outperform other companies in its industry.

  • Should You Buy Two Harbors Investment Corp (TWO)?
    Business
    Insider Monkey

    Should You Buy Two Harbors Investment Corp (TWO)?

    That's why we believe it isn't a waste of time to check out hedge fund sentiment before you invest in a stock like Two Harbors Investment Corp (NYSE:TWO). Two Harbors Investment Corp (NYSE:TWO) shares haven't seen a lot of action during the third quarter. Overall, hedge fund sentiment was unchanged.

  • Some GoPro (NASDAQ:GPRO) Shareholders Have Taken A Painful 92% Share Price Drop
    Business
    Simply Wall St.

    Some GoPro (NASDAQ:GPRO) Shareholders Have Taken A Painful 92% Share Price Drop

    Because GoPro is loss-making, we think the market is probably more focussed on revenue and revenue growth, at least for now. When a company doesn't make profits, we'd generally expect to see good revenue growth. Some companies are willing to postpone profitability to grow revenue faster, but in that case one does expect good top-line growth.

  • Crash shines light on immigrants in Christmas tree workforce
    News
    Associated Press

    Crash shines light on immigrants in Christmas tree workforce

    It was nighttime when Pedro Lucas came home, clutching receipts showing he had paid a funeral home to have the bodies of three immigrant laborers returned to Guatemala from Oregon. The three, including two of Lucas' cousins, were killed when a pickup truck slammed into a van carrying them and 10 other Guatemalans home from work at a Christmas tree farm. Lucas' father, who arrived in America just seven months ago and sent part of his earnings to his wife in the village of Chacaj, was also in the van and remains in a coma, his back broken.

  • The No. 1 highest paid, most in-demand jobs in every U.S. state for 2019
    Business
    MarketWatch

    The No. 1 highest paid, most in-demand jobs in every U.S. state for 2019

    Software developers, physical therapists and physician assistants crop up frequently among the highest-paid and fastest-growing jobs in every U.S. state, according to a recent analysis by CareerBuilder, a jobs and careers site. The site analyzed government data to project the careers most likely to be lucrative and in demand. Most of these jobs require some level of college education.

  • A Close Look At Verizon Communications Inc.’s (NYSE:VZ) 13% ROCE
    Business
    Simply Wall St.

    A Close Look At Verizon Communications Inc.’s (NYSE:VZ) 13% ROCE

    Today we'll evaluate Verizon Communications Inc. (NYSE:VZ) to determine whether it could have potential as an investment idea. Specifically, we're going to calculate its Return On Capital Employed (ROCE), in the hopes of getting some insight into the business. First up, we'll look at what ROCE is and how we calculate it.

  • Hedge Funds Have Never Been This Bullish On New Mountain Finance Corp. (NMFC)
    Business
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On New Mountain Finance Corp. (NMFC)

    The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Should you consider New Mountain Finance Corp. (NYSE:NMFC) for your portfolio? New Mountain Finance Corp. (NYSE:NMFC) shareholders have witnessed an increase in hedge fund interest lately.